Trader should monitor for pricing announcement and closing — given no minimum offering amount, the actual dilution could be low if demand is weak, but any issuance will materially increase the float. Watching for Series C warrant overhang (23.3M potential shares) as a persistent overhang that could cap any near-term rally.
Price Chart
Executive Summary
The SEC declared Sunshine Biopharma's S-1 registration statement effective on September 8, 2026, allowing the company to proceed with a best-efforts offering of up to 5,825,242 common units and 5,825,242 pre-funded units. Each unit consists of common stock or a pre-funded warrant plus two Series C warrants at an assumed price of $1.03 per unit, for maximum proceeds of $6 million. The effectiveness lifts the regulatory barrier to the offering, which has no minimum closing amount and will terminate by June 30, 2026, creating immediate dilution overhang for the sub-$5M market cap issuer.
Key Facts
- Effectiveness date: September 8, 2026, for S-1 registration covering up to $6,000,000 in securities.
- Offering: up to 5,825,242 common units (one share + two Series C warrants) and 5,825,242 pre-funded units (pre-funded warrant + two Series C warrants).
- Series C warrants have a $1.03 exercise price, exercisable for five years, adding potential for ~23.3M additional shares.
- No minimum offering amount required; proceeds could be substantially less than $6M.
- Best-efforts basis via Aegis Capital Corp.; placement agent not required to purchase or arrange any specific dollar amount.
- Common units and pre-funded units priced at $1.03 per unit (based on last sale on May 11, 2026), but final price may be discounted.
- Company has a tiny market cap of approximately $4M, making the offering highly dilutive relative to its size.
Financial Impact
Maximum gross proceeds of $6,000,000 from sale of up to 5,825,242 common units and 5,825,242 pre-funded units; full exercise of Series C warrants would bring in additional ~$12M but adds up to 23.3M shares, severely diluting the current ~$4M market cap issuer.
Risk Factors
- Massive dilution if full $6M offering is completed relative to current $4M market cap.
- No minimum offering amount — proceeds may be trivial, potentially failing to fund operations meaningfully.
- Series C warrants add long-term dilution overhang (5-year term) even if initial offering is small.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002914 |
| Document: 9999999995-26-002914-index.html | 9999999995-26-002914 |
| Document: 9999999995-26-002914.txt | 9999999995-26-002914 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $2.96 (+1118.11%) |
Oct 13, 2026 14d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $2.96 (+1118.11%) |
Oct 9, 2026 18d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $2.96 (−880.13%) |
Oct 9, 2026 18d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $2.96 (−880.13%) |
Oct 8, 2026 19d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | $2.96 (−588.37%) |
Oct 5, 2026 22d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | $2.96 (−643.91%) |
Oct 2, 2026 25d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | $2.96 (−604.59%) |
Sep 9, 2026 6w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | $2.96 (−164.29%) |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | $2.96 (+164.29%) |
Aug 3, 2026 12w ago | 8-K | $23.40 $24.40 | ▲ +4.27% | ▲ +2.25% | $2.96 (−87.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers